AAAAAA
Results: 1-25/30
Authors:
Piccart, M
Citation: M. Piccart, Early breast cancer - Chairman's introduction, EUR J CANC, 37, 2001, pp. S3-S4
Authors:
Piccart, M
Citation: M. Piccart, Interview - Martine Piccart, EUR J CANC, 37(3), 2001, pp. 295-295
Authors:
Piccart, M
Cataliotti, L
Buchanan, M
Freilich, G
Jassem, J
Citation: M. Piccart et al., Brussels Statement document, EUR J CANC, 37(11), 2001, pp. 1335-1337
Authors:
Piccart, M
Kaufmann, M
Citation: M. Piccart et M. Kaufmann, Herceptin: HER2 status - Changing clinical practice - Introduction, EUR J CANC, 37, 2001, pp. S1-S2
Authors:
Piccart, M
Citation: M. Piccart, Closing remarks and treatment guidelines, EUR J CANC, 37, 2001, pp. S30-S33
Authors:
Duffaud, F
van der Burg, MEL
Namer, M
Vergote, I
Willemse, PHB
Huinink, WT
Guastalla, JP
Nooij, MA
Kerbrat, P
Piccart, M
Tumolo, S
Favalli, G
van der Vange, N
Lacave, AJ
Wils, J
Splinter, TAW
Einhorn, N
Roozendaal, KJ
Rosso, R
Vermorken, JB
Citation: F. Duffaud et al., D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study, ANTI-CANC D, 12(2), 2001, pp. 159-162
Authors:
Oudard, S
Caty, A
Humblet, Y
Beauduin, M
Suc, E
Piccart, M
Rolland, F
Fumoleau, P
Bugat, R
Houyau, P
Monnier, A
Sun, X
Montcuquet, P
Breza, J
Novak, J
Gil, T
Chopin, D
Citation: S. Oudard et al., Phase II study of vinorelbine in patients with androgen-independent prostate cancer, ANN ONCOL, 12(6), 2001, pp. 847-852
Authors:
Cardoso, F
Di Leo, A
Larsimont, D
Gancberg, D
Rouas, G
Dolci, S
Ferreira, F
Paesmans, M
Piccart, M
Citation: F. Cardoso et al., Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes, ANN ONCOL, 12(5), 2001, pp. 615-620
Authors:
Piccart, M
Citation: M. Piccart, Untitled - Introduction, ANN ONCOL, 12, 2001, pp. 1-1
Authors:
Eskens, FALM
Awada, A
Cutler, DL
de Jonge, MJA
Luyten, GPM
Faber, MN
Statkevich, P
Sparreboom, A
Verweij, J
Hanauske, AR
Piccart, M
Citation: Falm. Eskens et al., Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors, J CL ONCOL, 19(4), 2001, pp. 1167-1175
Authors:
Bonnefoi, H
Biganzoli, L
Cufer, T
Mauriac, L
Hamilton, A
Schaefer, P
Piccart, M
Citation: H. Bonnefoi et al., An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of largeoperable or locally advanced/inflammatory breast cancer, BREAST CANC, 70(1), 2001, pp. 55-63
Authors:
Piccart, M
Lohrisch, C
Di Leo, A
Larsimont, D
Citation: M. Piccart et al., The predictive value of HER2 in breast cancer, ONCOL-BASEL, 61, 2001, pp. 73-82
Authors:
Klijn, JGM
Beex, LVAM
Mauriac, L
van Zijl, JA
Veyret, C
Wildiers, J
Jassem, J
Piccart, M
Burghouts, J
Becquart, D
Seynaeve, C
Mignolet, F
Duchateau, L
Citation: Jgm. Klijn et al., Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study, J NAT CANC, 92(11), 2000, pp. 903-911
Authors:
Gancberg, D
Lespagnard, L
Rouas, G
Paesmans, M
Piccart, M
Di Leo, A
Nogaret, JM
Hertens, D
Verhest, A
Larsimont, D
Citation: D. Gancberg et al., Sensitivity of HER-2/neu antibodies in archival tissue samples of invasivebreast carcinomas - Correlation with oncogene amplification in 160 cases, AM J CLIN P, 113(5), 2000, pp. 675-682
Authors:
Van den Neste, E
de Valeriola, D
Kerger, J
Bleiberg, H
Kusenda, Z
Brassinne, C
Bartholomeus, S
Selleslags, J
Hennebert, P
Wythouck, H
Cazenave, I
Lefresne-Soulas, F
Piccart, M
Citation: E. Van Den Neste et al., A Phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors, CLIN CANC R, 6(1), 2000, pp. 64-71
Authors:
Awada, A
Piccart, M
Citation: A. Awada et M. Piccart, Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents, CURR OPIN O, 12(4), 2000, pp. 289-296
Authors:
Piccart, M
Citation: M. Piccart, EORTC comment, EUR J CANC, 36(8), 2000, pp. 951-952
Authors:
Curran, D
Aaronson, N
Standaert, B
Molenberghs, G
Therasse, P
Ramirez, A
Koopmanschap, M
Erder, H
Piccart, M
Citation: D. Curran et al., Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study, EUR J CANC, 36(7), 2000, pp. 834-844
Authors:
Piccart, M
Goldhirsch, A
Straehle, C
Citation: M. Piccart et al., The Breast International Group: a new spirit of collaboration in breast cancer research for the new millennium, EUR J CANC, 36(14), 2000, pp. 1733-1736
Authors:
Kramer, JA
Curran, D
Piccart, M
de Haes, JCJM
Bruning, PF
Klijn, JGM
Bontenbal, M
van Pottelsberghe, C
Groenvold, M
Paridaens, R
Citation: Ja. Kramer et al., Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist, EUR J CANC, 36(12), 2000, pp. 1488-1497
Authors:
Kramer, JA
Curran, D
Piccart, M
de Haes, JCJM
Bruning, P
Klijn, J
Van Hoorebeeck, I
Paridaens, R
Citation: Ja. Kramer et al., Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer, EUR J CANC, 36(12), 2000, pp. 1498-1506
Authors:
Hamilton, A
Piccart, M
Citation: A. Hamilton et M. Piccart, The contribution of molecular markers to the prediction of response in thetreatment of breast cancer: A review of the literature on HER-2, p53and BCL-2, ANN ONCOL, 11(6), 2000, pp. 647-663
Authors:
Lohrisch, C
Piccart, M
Citation: C. Lohrisch et M. Piccart, Breast cancer: new aspects of adjuvant hormonal therapy, ANN ONCOL, 11, 2000, pp. 13-25
Authors:
Paridaens, R
Biganzoli, L
Bruning, P
Klijn, JGM
Gamucci, T
Houston, S
Coleman, R
Schachter, J
Van Vreckem, A
Sylvester, R
Awada, A
Wildiers, J
Piccart, M
Citation: R. Paridaens et al., Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over, J CL ONCOL, 18(4), 2000, pp. 724-733
Authors:
Hamilton, A
Roy, JA
Beex, L
Piccart, M
Mauriac, L
Coleman, R
Paridaens, R
Boes, GH
van Vreckem, A
Palmer, P
Klijn, J
Citation: A. Hamilton et al., EORTC 10941: A phase II study of liarozole in postmenopausal patients with'Chemotherapy-Resistant' or 'Potentially Hormone Sensitive' metastatic breast cancer, BREAST CANC, 60(2), 2000, pp. 181-188